In This Section

Julius Axelrod Award in Pharmacology Lecture

8:30 am - 9:20 am 

Paul Insel ProgramThe Julius Axelrod Award is presented annually for significant contributions to understanding the biochemical mechanisms underlying the pharmacological actions of drugs and for contributions to mentoring other pharmacologists. The Award was established in 1991 to honor the memory of the eminent American pharmacologist who shaped the fields of neuroscience, drug metabolism, and biochemistry and who served as a mentor for numerous eminent pharmacologists around the world.

Lessons from Endogenously Expressed GPCRs: Nature Knows Best!
Paul A. Insel - Univ. of California, San Diego

Julius Axelrod Symposium: Evolving Insights Regarding GPCRs: Compartmentation, Signaling and Clinical  Utility

9:30 am - 12:00 pm 

Sponsored by the John V. Croker Fund
Co-sponsored by the Divisions for Behavioral Pharmacology, Cancer Pharmacology, Cardiovascular Pharmacology, Drug Discovery and Development, Molecular Pharmacology, Neuropharmacology, and Translational and Clinical Pharmacology 

Paul Insel ProgramChair:
Paul A. Insel - Univ. of California, San Diego

This symposium will highlight several cutting edge aspects of GPCR biology and pharmacology. These aspects include structural biology, cellular and molecular analysis of signaling, functional roles of particular GPCRs in health and disease and efforts involved in developing and obtaining approval of novel GPCR drugs.

Paul A. Insel - Univ. of California, San Diego

Structure, Activation and Inhibition of Chemokine Receptors
Tracy M. Handel - Univ. of California, San Diego

The Membrane-intracellular Organelle Interface: A Compartment for GPCR Regulation of Cellular Metabolism and Function
Hemal H. Patel - Univ. of California, San Diego

cAMP Signaling Compartments: Adenylyl Cyclases as the Anchors
Rennolds S. Ostrom - Chapman Univ.

Beta-3 Adrenoceptor Agonists: A Case Study of Pharmacology in First-in-class GPCR Drug Discovery and Development
Martin C. Michel - Johannes Gutenberg Univ.

Panel Discussion  

Mushrooming Potential of Psychedelics as Therapeutics

9:30 am - 12:00 pm 

William Fantegrossi ProgramBEH Web TrackSponsored by the Division for Behavioral Pharmacology (BEH)
Co-sponsored by the Divisions for Neuropharmacology, Toxicology, and Translational and Clinical Pharmacology 

William E. Fantegrossi - Univ. of Arkansas for Medical Sciences
Roland Griffiths - Johns Hopkins Univ. Sch. of Med.

Roland Griffiths ProgramStudy of the therapeutic potential of hallucinogenic drugs has historically been considered somewhat esoteric, but the pharmacology of these agents has been well described, and their therapeutic efficacy is currently being established. This symposium will take a "bench to bedside" approach to review advancements in the study of hallucinogenic drugs, paying particular attention to preclinical behavioral pharmacology and neuropharmacology, as well as human psychopharmacology. As clinical interest in the therapeutic potential of these compounds is once again beginning to emerge, it is important to understand the dramatically expanded understanding of hallucinogen pharmacology that has been developed in recent years.

Animal Models of Hallucinogens and Serotonin 5-HT2A Receptor Neuropharmacology
Javier Gonzalez-Maeso - Virginia Commonwealth Univ.

Therapeutic Potential of 5-HT2A Agonists for Psychiatric Disorders: Are Psychedelic Effects Necessary?
Clinton Canal - Northeastern Univ.

Human Psychopharmacology of Hallucinogens
Theresa Carbonaro - Johns Hopkins Univ. Sch. of Med.

Hallucinogens as Novel Psychotherapeutics
Roland Griffiths - Johns Hopkins Univ. Sch. of Med.

Panel Discussion
William E. Fantegrossi - Univ. of Arkansas for Medical Sciences

Perinatal Therapeutics and the Programming of Adult Cardiometabolic Disease

9:30 am - 12:00 pm 

Stephane Bourque ProgramCVP Web TrackSponsored by the Division for Cardiovascular Pharmacology (CVP)
Co-sponsored by the Divisions for Drug Discovery and Development and Translational and Clinical Pharmacology 

Stephane L. Bourque - Univ. of Alberta
Stella Goulopoulou - Univ. of North Texas Health Science Center

Stella Goulopoulou ProgramThe developmental origins of health and disease (DOHaD) theory posits that susceptibility to cardiometabolic diseases may be 'programmed' by stressors during pregnancy and the immediate postnatal period. Targeted therapies during critical windows of development have the potential to provide lasting benefits and improve long-term health to the offspring. Potential targets for pharmacological intervention include reactive oxygen species, epigenetic alterations, the renin-angiotensin system, and cellular senescence. This symposium aims to create a forum for discussion to address recent advances in the use of therapeutics during gestation and postpartum, and discuss limitations in their use.

Stephane L. Bourque - Univ. of Alberta
Stella Goulopoulou - Univ. of North Texas Health Science Center

Epigenetics and the Developmental Origins of Obesity, Type 2 Diabetes,  and Cardiovascular Disease: Known, Unknowns and Possibilities
Susan Ozanne - Univ. of Cambridge

Gestational Diabetes and Fetal Programming of Metabolic Function: Mechanisms and Interventions
Vernon Dolinsky - Univ. of Manitoba

Early Postnatal Interventions for the Sex-specific Programming of Cardiovascular Dysfunction by Prenatal Hypoxia
Sandra T. Davidge - Univ. of Alberta

The RAS as a Therapeutic Target for the Fetal Programming of Cardiovascular Disease
Karen Moritz - The Univ. of Queensland

Gestational Exposure to Engineered Nanomaterials Effects Microvascular Health of Young Progeny
Phoebe A. Stapleton - Rutgers University

Fetal Betamethasone Exposure Markedly Attenuates the Protein Expression of Angiotensin Converting Enzyme 2 but not Dipeptidyl Peptidase 3 within the Brain Dorsomedial Medulla of Adult Female Sheep
Alexa S. Hendricks - Wake Forest School of Medicine

Emerging Technologies for Selectively Modulating the Tumor Immune Contexture

9:30 am - 12:00 pm 

Shiladitya Sengupta ProgramDDD Web TrackSponsored by the Division for Drug Discovery and Development (DDD)
Co-sponsored by the Division for Cancer Pharmacology (DCP) 

Shiladitya Sengupta - Harvard Medical School Medicine
Ashish A. Kulkarni - Brigham and Women's Hospital

Immunotherapy is revolutionizing the treatment of cancer. Immune checkpoint inhibitors that activate T cells are already in the clinics. However, several frontiers in cancer immunotherapy remain to be explored. For example, can we design next generation therapeutics that selectively modulate the tumor immune contexture while sparing the systemic immune components. What are the emerging paradigms in other areas of cancer immunology besides adaptive T cell-based immunotherapy? How can we monitor if immunotherapy is working or not? The symposium will address some of the emerging technologies that are addressing these unmet challenges.

Engineering Enhanced Cancer Vaccines
Darrell Irvine - Massachusetts Inst. of Technology

Supramolecular Therapeutics that Selectively Modulate the Tumor Immune Contexture
Shiladitya Sengupta - Harvard Med. Sch.

Targeting the Immune Cells for Anticancer Efficacy
Puja Sapra - Pfizer, Inc.

Imaging an Immunotherapy Response in Real-time
Ashish A. Kulkarni - Brigham and Women's Hospital, Harvard Med. Sch.

Peptide-Based Targeted Delivery for Immune Modulation
Hongbo Pang - Burnham Institute

Quantitative Systems Pharmacology: Application to Cancer Drug Development and Personalized/Precision Medicine

9:30 am - 12:00 pm 

Jessie Au ProgramTCP Web TrackSponsored by the Division for Translational and Clinical Pharmacology (TCP)
Co-sponsored by the Divisions for Cancer Pharmacology, Cardiovascular Pharmacology, Drug Discovery and Development, Drug Metabolism, Molecular Pharmacology, Neuropharmacology, Pharmacology Education, and Toxicology 

Jessie L.S. Au - Optimum Therapeutics LLC, Inst. of Quantitative Systems Pharmacology, Univ. of Oklahoma, Taipei Med. Univ., The Ohio State Univ.
Jerry S.H. Lee - National Cancer Institute

Jerry Lee ProgramSuccessful therapy requires delivering the right drug to the right target at the right concentration and at the right time, so that the maximum therapeutic effect is achieved and off-target effect is minimized. Targeted therapy matches the drug’s intended target to the patient’s molecular signature. The missing piece is finding the right dosing regimen so that the drug presentation to the target site is optimized to yield the desired time course of drug actions. The current presentation discusses an emerging research field, quantitative systems pharmacology, which has the potential of guiding the translation of laboratory information to facilitate drug development.

Application of QSP in Therapy Development: Intravesical Bladder Cancer Therapy as an Example
Jessie L.S. Au - Univ. of Oklahoma Health Sciences Center

Development of Next Generation Nanomedicines in Context of Overall NCI Oncology Strategies
Piotr Grodzinski - National Cancer Institute

Using Novel Quantitative Approach to Under Association Between the Biological Targets and Adverse Reactions for Tyrosine Kinase Inhibitors
Liang Zhao - US Food and Drug Administration

Translational Bioinformatics Research in Drug Interaction and Its Application in the Precision Medicine
Lang Li - Indiana Univ.

A Quantitative Systems Pharmacology Approach to Antiangiogenic Therapy
Sukung Woo - Univ. of Oklahoma Health Sciences Center

Science and Government: How to Make a Difference Through Advocacy

9:30 am - 12:00 pm 

Allyson Marshall ProgramSponsored by the 2016 Washington Fellows
Co-sponsored by all divisions 

Allyson C. Marshall - TKL Research, Inc.
Naeem Patil - Vanderbilt Univ. Medical Ctr.

Naeem Patil ProgramThis symposium is designed to educate the greater ASPET/EB community about the legislative process, how it can impact research, and ways to get involved.  Attendees will gain a better understanding about how the legislative/appropriations process works with a specific focus on setting funding levels. Speakers will discuss the impact of science policy issues on the NIH, academic institutions, and pharmaceutical companies. Attendees will gain training in how to construct an effective advocacy message and how individual scientists can help. The ASPET Washington Fellows program will be discussed in order to provide information about this important training opportunity.

Looking for a Few Good Fellows: The Critical Role of Early Career Scientists in Advocacy
Kenneth E. Thummel – Univ. of Washington
Susanna Aguirre - ASPET 

From the Bench to International Affairs: Life as a Science Diplomat
Chad R. Jackson - Universal Solutions International, Inc. (USI, Inc.)

Getting Involved Early: How Young Scientists Can Make a Difference
Debra A. Cooper - California Senate Office of Research

Bridging the Gap for Drug Development
Dennis C. Marshall - Ferring Pharmaceuticals, Inc.

Finding Your Voice: How to be an Advocate for Science
Yvette Seger - FASEB

Panel Discussion 

ASPET Poster Presentations

12:30 pm – 2:30 pm 

David Lehr Research Award Lecture

2:00 pm - 2:50 pm 

Doo-Sup Choi ProgramThe David Lehr Research Award is intended to extend funding for preclinical or clinical research directed towards improving human health. The inaugral recipient of the award in 2015 will present his research.

Adenosine-Regulated Glutamate Signaling in Neuron-Glia Interaction and Alcoholism
Doo-Sup Choi - Mayo Clinic College of Medicine

Big Ideas BadgeSurmounting the Insurmountable: Obstacles in Drug Discovery and Development – Real World Case Studies

3:00 pm - 5:30 pm 

 DDD Web TrackSponsored by the Division for Drug Discovery and Development (DDD)
Kan He ProgramCo-sponsored by the Division for Drug Metabolism (DM) 

Kan He - Biotranex, LLC
Paul F. Hollenberg - Univ. of Michigan

Paul F. Hollenberg ProgramThis session could also be called The Sherlock Holmes of the Lab: Solving Problems When Things Go Wrong in Drug Discovery and Development. During the drug discovery and development process in the real world, expert scientists frequently encounter an unexpected obstacle that seems insurmountable. Suddenly, the entire program is threatened and timetables are in a tailspin. Serious issues with efficacy, toxicity, and pharmacokinetics may unexpectedly threaten the successful development of the whole project. How do experienced scientists deal with such issues? Critical thinking and problem solving are essential for success. This session features recognized experts in drug discovery and development and their fascinating and challenging stories. Scientists and managers, from experienced experts to grad students will learn the “inside story” of detailed real world case studies. What went fatally wrong with a particular drug? How was the problem solved? It’s like a Sherlock Holmes story: here’s the mystery, find out who solved it and how. 

This workshop is a product of the ASPET BIG IDEAS initiative approved by the ASPET Council in 2016.

Sustiva: A Rescue from Death Due to Nonclinical Toxicity
Gerald T. Miwa - Univ. of North Carolina, Eshelman Sch. of Pharmacy

Challenges in the Discovery and Development of Vorapaxar, A Novel Antiplatelet Drug
Madhu S. Chintala - Johnson & Johnson

Empagliflozin: Sex, Species, and Tissue-Specific Metabolism
Mitchell E. Taub – Boehringer Ingelheim Pharmaceuticals

Apixaban: How Volume of Distribution Became Critical in Optimizing Efficacy and Minimizing Toxicity
Kan He - Biotranex, LLC

Division for Neuropharmacology Postdoctoral Scientist Award Finalists

NEU Web Track3:00 pm - 5:30 pm 

Presentations are selected from postdoctoral applicants to the ASPET Best Presentation Awards. 

Estrous Cycle-Dependent Alterations in Cocaine Affinity at the Dopamine Transporter Underlie Enhanced Cocaine Reward in Remales
Erin Calipari - Icahn School of Medicine at Mount Sinai

Cortical Circuit Dynamics during Punishment-Resistant Alcohol Drinking
Cody Siciliano - Massachusetts Institute of Technology

Altered Kisspeptin Responsiveness in Bmal1 Knockout Females
Karen Tonsfeldt - University of California San Diego

The Neuroprotective Role of Myeloid Zinc Finger-1 and Specificity Protein 1 during Treatment with Leukemia Inhibitory Factor
Stephanie Davis - University of Kentucky

A G Protein-Biased Ligand of the Kappa Opioid Receptor is Antinociceptive and Antipruritic but Does Not Cause Sedation or Dysphoria
Tarsis Brust - The Scripps Research Institute

Organic Cation Transporter 3 Upregulation in Serotonin Transporter Deficient Mice Potentiates Ethanol-Induced Serotonin Clearance Impairments
T. Lee Gilman - University of Texas Health Science Center at San Antonio

Pharmacologic Inhibition and Genetic Elimination of p38α MAPK Normalizes Serotonergic System Alterations and Social Behavior Deficits in the SERT Ala56 Mouse Model of Autism Spectrum Disorder
Matthew Robson - Florida Atlantic University.

Endogenous Melatonin Decreases Place Preference for Methamphetamine through a Learning and Memory Independent Mechanism in C57BL/6 Mice
Shannon Clough - Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY

Blockade of a Novel Neuropeptide Receptor System, BigLEN-GPR171, Reduces Adverse Effects of Prolonged Morphine Administration
Erin Bobeck - Icahn School of Medicine at Mount Sinai

Enhanced Mitochondrial Biogenesis for the Treatment of Spinal Cord Injury
Natalie Scholpa - University of Arizona

Division for Behavioral Pharmacology – Team Science Forum: Scientist Crosstalk on Chemistry and Behavior

BEH Web Track3:00 pm - 5:30 pm 

Emily Jutkiewicz – Univ. of Michigan Medical School
Bruce Blough - Research Triangle Institute

The symposium/workshop will focus on the highly collaborative interactions between medicinal chemists and behavioral pharmacologists in the development and investigation of novel therapeutics. Pairs of speakers will describe findings ranging from chemical design and synthesis to in vivo evaluation of a single class of compounds. Importantly, these teams will demonstrate how scientists from these different fields communicate and educate each other, emphasizing the challenges and successes of these important scientific relationships.

Pair 1: Development of GlyT-1 Inhibitors for the Treatment of Psychiatric Disorders
Peter Guzzo - ConSynance Therapeutics, Inc.
Nicholas Moore - Brains-Online

Pair 2: Designing Mixed Efficacy Opioid Ligands with Improved Analgesic Profiles
Henry Mosberg – Univ. of Michigan
Emily Jutkiewicz – Univ. of Michigan

Pair 3. Optimizing in Vivo Pharmacology of Short-Acting Cannabinoid Ligands
Alex Makriyannis - Northeastern Univ.
Carol Paronis - McLean Hosp., Harvard Univ. Med. Sch.

Division for Translational and Clinical Pharmacology - Young Investigator Awards Platform Session and Early Career Faculty Showcase

TCP Web Track3:00 pm - 6:00 pm 

These platform presentations are selected from applicants to the abstract topic category called “3036-ASPET Translational and Clinical Pharmacology Trainee Showcase.”

Novel Characterization of Docohexanoic Acid and Its 12-LOX Products, 11-HDHE and 14-HDHE on Human Blood Platelets
Megan Hawley - University of Michigan Medical School

Inhibition of Neuropilin 1 Signaling in Glioma Associated Macrophages and Microglia Slows Tumor Progression
Jeremy Miyauchi - Stony Brook University

Ursolic Acid from Shea Butter Tree (Vitellaria Paradoxa) Leaf Extract Synergizes with 6-Lactams against Methicillin-Resistant Staphylococcus Aureus
Lucy Catteau - Université Catholique de Louvain (UCL)

11/14-oxy-DPA, the 12-LOX Derived Metabolites of DPA, Inhibit Platelet Activation Through the cGMP-PKG Signaling Pathway
Jennifer Yeung - University of Michigan

Treatment with Anti-PD-L1 Antibody Improves Antimicrobial Immunity during Burn Wound Sepsis
Naeem Patil - Vanderbilt University Medical Center

Drugging the Gut Microbiome for the Treatment of Alcohol-Induced Liver Injury
Robert Helsley - Cleveland Clinic Foundation

Early Career Faculty Showcase  

Discontinuation of Chronic RAAS Inhibitor Therapy at Time of Contrast Media Administration Reduces Degree of Kidney Injury in an Animal Model
D. Adam Lauver – Michigan State University

High-calorie Diet Induces Vascular and Hemodynamic Abnormalities in Absence of Change in Blood Glucose or Insulin Levels: Modulation by Oral Anti-hyperglycemic Drugs
Ahmed El-Yazbi - American University of Beirut

Division for Cancer Pharmacology – Young Investigators Symposium

DCP Web Track3:00 pm - 5:30 pm 

Abstract-based presentations will be selected from applicants to the following Cancer Pharmacology abstract topic categories: 3000-ASPET, 3001-ASPET, 3002-ASPET, and 3003-ASPET.  

Lipidomic Profiling Identifies Cytochrome P450 as A Therapeutic Target for Colitis-Associated Colorectal Cancer
Weicang Wang - University of Massachusetts

The Interaction of GIV with Galpha-i is a Druggable Protein-Protein Interaction
Vincent DiGiacomo - Boston University School of Medicine

A Constitutive Androstane Receptor (CAR) Inhibitor CINPA1 as a Tool to Understand Receptor Structure and Function
Milu Cherian - St Jude Children's Research Hospital

Oncolytic Adenovirus Expressing IFN-α Synergistically Potentiates Chemotherapy, Radiation, and Chemoradiation in Pancreatic Cancer Cells
Amanda Salzwedel - University of Minnesota

cAMP-Phosphodiesterase PDE4D as a Target for Colon Cancer Therapy
Abigail Boyd - University of South Alabama

Non-Cannonical Notch Signaling Pathways Regulate Breast Cancer Stem-like Cells Function in Triple Negative Breast Cancer
Fokhrul Hossain - LSUHSC

Division for Toxicology – In Utero and Neonatal Exposure to Environmental Agents

TOX Web Track3:00 pm - 5:30 pm 

Monica Valentovic - Marshall Univ. School of Medicine

This symposium will discuss the exposure of the developing fetus and the newborn to various environmental chemicals that may induce a predisposition to disease or abnormal function. The mechanisms of toxicity are not well understood for environmental chemical exposure to the fetus or the newborn. Limited information also exists regarding the various agents that can be detected in the developing fetus and newborn. This symposium will discuss clinical studies evaluating environmental chemicals detected in umbilical cord blood samples. This symposium will also present findings from rodent research models to evaluate the mechanisms of toxicity.

Introduction and Presentation of Division for Toxicology Career Award
Lauren Aleksunes - Rutgers Univ.

Prenatal Exposure Resulting in PAH-DNA Adducts in Umbilical Cord Blood
Monica Valentovic –Marshall Univ. School of Medicine

Human Prenatal Exposure to Essential and Toxic Elements
Jesse Cottrell – Marshall Univ. School of Med. / Univ. of Mississippi Med. Ctr.

Age-Related Changes in the Disposition of Pyrethroid Insecticides
Catherine White – Univ. of Georgia

Microvascular Ramifications of Maternal Nanomaterial Inhalation: Uterine and Fetal Perspectives
Tim Nurkiewicz – West Virginia Univ.

Gestational Nanomaterial Exposures: The Next Generation
Phoebe Stapleton – Rutgers Univ. School of Pharmacy

Division Annual Meetings

5:30 pm – 6:30 pm 

Participate in your division's annual meeting to discuss division activities, symposium proposals for EB2018, how to get involved, and much more.  On Tuesday, the following divisions will meet: 

  • Behavioral Pharmacology
  • Cancer Pharmacology
  • Neuropharmacology
  • Translational and Clinical Pharmacology
  • Toxicology

Division Mixers

6:30 pm – 8:30 pm 

Interact face-to-face with other ASPET members with similar research interests.  Attend the mixer hosted by your primary and/or secondary divisions.  More information about ASPET divisions and how to select one.

On Tuesday, the following division mixers will be held:

  • Joint Mixer: Divisions for Behavioral Pharmacology and Neuropharmacology
  • Joint Mixer: Divisions for Cancer Pharmacology, Translational and Clinical Pharmacology, Drug Discovery and Development, and Pharmacology Education

Last updated: April 18, 2017 

Job Postings